miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 23, 2026

Bitcoin Decline Hasn't Changed The Thesis For Institutional Investors, Coinbase Chief Institutional Strategist Says

View original at finance.yahoo.com
Bitcoin Decline Hasn't Changed The Thesis For Institutional Investors, Coinbase Chief Institutional Strategist Says Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bitcoin unlikely to reach $15,000 levels again due to reduced volatility and favorable U.S. administration

    80% confidence

  • 10-year returns: S&P made 2.5x, gold made 3x, Bitcoin made 11,000-15,000x

    80% confidence

  • Institutional investors' thesis of Bitcoin as store of value has not changed despite price volatility

    80% confidence

  • Institutional investors in Hong Kong and UAE are leveraging natural resources to buy and hold Bitcoin

    80% confidence

  • Institutional investors are investing very heavily in adopting blockchain technology for infrastructure

    80% confidence

  • Bitcoin's recent decline is a setup seen multiple times before

    80% confidence

  • Middle East investors use fossil fuel sales for Bitcoin investment, China uses trade surpluses

    80% confidence

  • Net buying exceeds net selling on Coinbase platform

    80% confidence

  • Institutional investors have been investing consistently over past five to seven years, not just buying the dip

    80% confidence

Data points we hold from this source

Elf Labs · trademarks copyrights500 count
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com